Clinical Pharmacokinetics of Ciprofloxacin

Medicine & Life Sciences

• Ciprofloxacin 100%
• Pharmacokinetics 72%
• Fluoroquinolones 25%
• Quinolones 15%
• DNA Gyrase 13%
• Elderly 9%
• Cystic Fibrosis 8%
• Serum 8%
• Oral Administration 7%
• Pharmaceutical Preparations 7%
• High Pressure Liquid Chromatography 7%
• Kidney 7%
• Nutrition Disorders 6%
• Sucralfate 6%
• Lactams 6%
• Bacteria 6%
• Nalidixic Acid 6%
• Anti-Bacterial Agents 5%
• Antacids 5%
• Type II DNA Topoisomerase 5%
• Bacterial DNA 5%
• Xanthine 5%
• R Factors 5%
• Hepatobiliary Elimination 5%
• Aluminum 5%
• Theophylline 5%
• Prothrombin Time 5%
• Dosage Forms 5%
• Mutation 5%
• Aminoglycosides 5%
• Enzymes 4%
• Peritoneal Dialysis 4%
• Warfarin 4%
• Magnesium 4%
• Zinc 4%
• Agar 4%
• Half-Life 4%
• Nausea 4%
• Renal Insufficiency 4%
• Chronic Kidney Failure 4%
• Gastrointestinal Tract 3%
• Renal Dialysis 3%
• Vomiting 3%
• Permeability 3%
• Liver Diseases 3%
• Iron 3%
• Diarrhea 3%
• Mucous Membrane 3%
• Stomach 3%
• Food 3%
• Research Personnel 3%
• Calcium 3%
• Incidence 2%
• In Vitro Techniques 1%
• Population 1%
• Therapeutics 0%